Novartis hails Genmab drug
![Foto: /ritzau/AP/Steffen Schmidt/](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article7398278.ece/ALTERNATES/schema-16_9/POLFOTO_4495693.jpg)
Sales numbers have been rather disappointing so far, but Swiss-based drug group Novartis is not about to give up on Genmab’s cancer drug Arzerra (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL), the most common form of leukemia in the Western world.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danske Capital: Exit is a massive boost for Genmab
For abonnenter
This is Genmab’s main focus for 2015
For abonnenter
Danske: Genmab partner might accelerate launch
For abonnenter